Effect of Low-Dose Esketamine on Postoperative Delirium in Elderly Patients Undergoing Total Hip or Knee Arthroplasty: A Randomized Controlled Trial
Chao-Bang Ma,Cheng-Yang Zhang,Cai-Li Gou,Zeng-Hui Liang,Jing-Xian Zhang,Fei Xing,Jing-Jing Yuan,Xin Wei,Ya-Bing Zhang,Zhong-Yu Wang
DOI: https://doi.org/10.2147/dddt.s477342
IF: 4.3188
2024-11-28
Drug Design Development and Therapy
Abstract:Chao-Bang Ma, 1, &ast Cheng-Yang Zhang, 1, &ast Cai-Li Gou, 1 Zeng-Hui Liang, 1 Jing-Xian Zhang, 2 Fei Xing, 1, 3 Jing-Jing Yuan, 1, 3 Xin Wei, 1, 3 Ya-Bing Zhang, 1 Zhong-Yu Wang 1, 3 1 Department of Anesthesiology, Pain and Perioperative Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, People's Republic of China; 3 Henan Province International Joint Laboratory of Pain, Cognition and Emotion, Zhengzhou, Henan Province, People's Republic of China; 2 The Surgical Department of the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zhong-Yu Wang, Department of Anesthesiology, Pain and Perioperative Medicine, the First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Erqi District, Zhengzhou City, Henan Province, People's Republic of China, Tel +86-13937165514, Email Purpose: Postoperative delirium (POD) is a prevalent and severe complication in elderly patients undergoing major surgery, associated with increased morbidity and mortality. This randomized controlled trial aimed to investigate the effects of low-dose esketamine on the incidence of POD in elderly patients underwent total hip or knee arthroplasty. Patients and Methods: Two hundred and sixty elderly participants were randomly assigned to either the esketamine group (Group E) (0.20mg/kg loading, 0.125mg/kg/h infusion, 0.5 mg/kg for postoperative analgesia) or the placebo group (Group P) (received normal saline). The primary outcome was the incidence of POD, with secondary outcomes including delirium subtypes, duration, intraoperative analgesic consumption, operative and anesthesia times, hemodynamic changes, postoperative pain scores, sleep quality, and common postoperative adverse events. Results: There was no significant difference in the incidence of POD between Group E (8.5%) and Group P (10.8%). No significant differences were observed for the time of delirium onset, duration of delirium, and delirium subtype between the two groups. Patients in the esketamine group had more stable hemodynamic profile after induction and reduced the pain score of motion on the first two days postoperatively but increased the incidence of postoperative dizziness. Conclusion: The repeated infusion of low-dose esketamine did not reduce the incidence of POD during the initial three postoperative days in elderly patients following total hip or knee arthroplasty. Keywords: esketamine, delirium, aged, arthroplasty With the increasing severity of population aging, obesity, and metabolic issues, bone and joint diseases among the elderly have become increasingly prominent, making surgical intervention a necessary treatment option in many cases. 1 Total hip arthroplasty (THA) and total knee arthroplasty (TKA) are established and efficacious treatments for end-stage degenerative diseases of the hip and knee. 2 However, postoperative delirium (POD), one of the dominant complications usually occurs in elderly patients after major surgery, results in delayed recovery, extended hospital stays, and even related mortality. 3 The etiology of delirium is multifactorial, and its pathophysiology remains elusive, making prevention and management particularly challenging. Pain, opioid analgesia, and the inflammatory response to surgery are all implicated as potential risk factors for POD. 4 Esketamine, the S-enantiomer of ketamine, exhibits a significantly higher affinity for the glutamate N-methyl-D-aspartic acid receptor (NMDAR). 5 Ketamine selectively inhibits calcium influx and reduces γ-aminobutyric acid (GABA) release by binding to NMDAR on inhibitory neurons. This action decreases GABAergic inhibition, leading to enhanced glutamate neurotransmission. Glutamate activates α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptors (AMPARs) and triggers brain-derived neurotrophic factor (BDNF) release. BDNF, via tropomyosin receptor kinase B (TrkB) receptors, activates the mammalian target of rapamycin (mTOR) pathway, promoting synaptic protein synthesis and dendritic spine formation, strengthening cortical connectivity. 6,7 It is also believed to exert a neuroprotective effect by suppressing the inflammatory response to surgery, 8 so it may prevent POD in elderly patients. This hypothesis has inspired several trials to test the impact of subanesthetic doses of ketamine on the risk of POD. 9–11 However, these studies have not -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal